FL
Nice to hear about your personal background and your place of living: the flat countries of Chigago.:) I whish you all the best for 2020 and I appreciate you highly!
"I apologize for my brief hiatus from posting. Between year end business, Christmas and the presidential impeachment hearings, I have found it hard to find time to post. It does not reflect a diminished outlook for BCART! I kind of laughed at some of the guesses about my background. I'm not trying to hide anything so I'll put it out there. I'm an engineer in the Chicago area in my 50's (yes it is quite flat here). I have no connection to BCART other than my investment. I have invested in genomic testing companies for nearly 20 years. Some of my previous investments in this area included: Vysis, Foundation Med and Genomic Health. As I have said beforIe, I like BCART since it offers a platform that reduces time and costs and not just an assay or two. I'm also a shareholder in NVS. Part of the reason I invested in Novartis many years ago was its (Sandoz) leadership position in biogenerics. I believe Biogeneric legislation in the EU was and still is years ahead of the US FDA policy. I think genomic IVD approvals is another area where the EU leads the FDA in the US . However, it is tough and often painful waiting for the legislation to catch up. In the case of biogenerics major US players were able to influence FDA Biogeneric legislation. I think BCART is smart to have partnered with many of the Big Pharma companies that are likely to influence the Companion Diagnostic (CDx) IVD approval decision making process in the US."
Any way: I was right about the fact that you have a lot of years of experience in the genomic testing fields/MDx field.
Wasn't to hard.
"It is my belief that the current sentiment rather than fundamentals are the biggest current drag of the BCART share price. The sentiment can be attributed to several factors.
1) Currently the the animal spirits are running much stronger in the US than in Europe. This is a function of the 11 year bull market in the US. Being a contrarian, this one thing I found attractive about BCART and the Brussels market. I'd much rather buy on the cheap and wait. These things have a way of going thru cycles."
I do not agree with you here at all: the only reason BCART fell back as much as it did was because of the fall-back in growth and the bad reputations of the other European players in the field of the MDx market like Curetis > down over 100%, MDxHealth, > down over 100%, Epigenomics, > down over 100%! Etc. This is the first thing investorts refer too in uncertain new fields/markets like MDx. All mentioned stocks started promising!!
2) BCART was getting some exposure in the US through GHDX and their very positive mentions during the conference calls. Since the merger with EXAS, this coverage has evaporated over the past 4 or 5 months.
You could have a point here!
3) The US is the largest capital market in the world, and BCART has been all but isolated from private investors in this market. Schwab (the largest US brokerage) has blocked trading of BCART. I had to open an account at Interactive Brokers to maintain trading access.
This is something I would like to know more about!
"4) there has been a dearth of news on BCART. This perplexed me for a while. Why not re-post the Septicyte news since it is freely accessible on the ImmunExpress website? Why not announce that the OncoDx Breast cartridges have peen placed at various hospitals for validation testing? Some of this might be (as I previously hypothesized) an effort not to run afoul of partners. It may also be an effort to fly below the radar. BCART is a very small company that could easily be outspent if a larger testing company made a decision to make headway in a given market (i.e., European Breast cancer treatment). Perhaps they feel completing validation, and gaining first mover advantage without fanfare will provide them an advantage. At some point in the near future (I think when OncoDX receives EU Marking) they with their partner will move to increase the visibility of the tests."
Isn’t it a matter of fact that BCART has a technological advantage?
"In my previous post, I did not mean to convey that I was incredulous about MB call with BCART investor relations. What I meant was things in the US are very litigious, .and firms traded on the NYSE or NASDAQ have instructed their investor relation departments not to release any information that could be misunderstood or used as fodder in a lawsuit."
You should know that I wrote - prior to the answers to the questions – that I was not sure at all that I would provide the exact answers. It was for me in a harsh way a check upon BCART, no matter what it would cost me. I have a lot to lose as an investor: in fact the chance I lose money is over 90% in biotech. There is very little I know for sure as a small man investor. Why I should leave a chance to keep them sharp???
"Some of the speculation as to what BCART might be worth in 2030 is interesting. There are a lot of variables that come into play. I have hypothesized that BCART exhibits a lot of similarities to Cepheid. Cepheid went from $5 to $50 in pretty short order after the company increased sales of its Gene Expert system. I think BCART is capable of a 10 fold increase over the next five years let alone 10 yrs. Currently, EXAS and GH have total market capitalization's of 7 to 13 billion. Given the platform reviews,potential for worldwide adoption, I don't see a reason why BCART achieve a market Cap approaching 5 to 10$B in the next 10 years. As I have mentioned before, the design of the BCART console would appear amenable for first line diagnostic use. It might also be useful in disseminating educational information. Partner sponsored ads/educational materials could be very lucrative at some point if BCART grows the installed base."
"I generally like to look at shorter time frame execution milestones but it is the end of the year and New Years is a time for looking forward and projections. "
I do agree with you on this matter, but BCART should make the steps in 2020 or beginning 2021. Other wise I will step out and do not believe in the story anymore. In my view: the Partner sponsored ads/educational materials as an extra income or even more than that is not something I would rely on.
MB (Happy Chrismas, and thank you very much for contributions and feel welcome anytime to write me whatever comes to mind)